How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,712 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension

Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension (RACE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2015 Clinical Trials

162. Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

are randomised to receive either Rivaroxaban or the standard treatment with low-molecular heparin. Condition or disease Intervention/treatment Phase Venous Thromboembolism Cancer Drug: Rivaroxaban Drug: low-molecular heparine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 450 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title (...) thrombocytopenia II pregnant or breast-feeding women. Women of child-bearing potential must have a negative pregnancy test performed < 7 days prior to start of the treatment severe renal insufficiency (GFR < 30 ml/min) liver disease with coagulation impairment, including Child B and C cirrhosis acute medical illness treatment of the underlying cancer with experimental therapies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2015 Clinical Trials

163. Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE Condition or disease Intervention/treatment Phase Cerebral Vein Thrombosis Deep Vein Thrombosis (...) Embolism Venous Thromboembolism Pulmonary Embolism Venous Thrombosis Neoplasms, Second Primary Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Apixaban Dalteparin Heparin, Low-Molecular-Weight Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents

2015 Clinical Trials

164. Computed Tomography CT Venography During Postpartum Venous Thromboembolism

embolism (PE) results in a gain in venous thromboembolism detection rate. Condition or disease Intervention/treatment Phase Pulmonary Thromboembolism Procedure: computed tomography venography Not Applicable Detailed Description: Pulmonary embolism (PE) remains a leading cause of maternal death during postpartum in developed countries; Thoracic computed tomography angiography (CTA) is the first-line diagnostic test for PE suspicion, but has a 20 to 35% rate of inconclusiveness during pregnancy (...) Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Embolism

2015 Clinical Trials

165. Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients

enoxaparin dosing strategies. Condition or disease Intervention/treatment Phase Traumatic Injury Venous Thromboembolism Drug: Enoxaparin 40 mg q12h Drug: Enoxaparin 30 mg q8h Phase 4 Detailed Description: This is a pilot study to determine if AT-III serum concentrations differ between patients with normal (>= 0.1 IU/mL) versus subtherapeutic (<0.1 IU/mL) anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for venous thromboembolism (VTE) prophylaxis. Secondarily, this study (...) table for MeSH terms Thromboembolism Venous Thromboembolism Wounds and Injuries Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Heparin, Low-Molecular-Weight Dalteparin Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action

2015 Clinical Trials

166. Epidemiology of venous thromboembolism. (PubMed)

Epidemiology of venous thromboembolism. Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is a fairly common disease, particularly in older age, and is associated with reduced survival, substantial health-care costs, and a high rate of recurrence. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis (...) and various risk factors. Major risk factors for incident VTE include hospitalization for surgery or acute illness, active cancer, neurological disease with leg paresis, nursing-home confinement, trauma or fracture, superficial vein thrombosis, and-in women-pregnancy and puerperium, oral contraception, and hormone therapy. Although independent risk factors for incident VTE and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence

Full Text available with Trip Pro

2015 Nature reviews. Cardiology

167. Statement on pregnancy and travel

of toxemia, hypertension, or diabetes with any pregnancy / Antécédents de toxémie, d’hypertension artérielle ou de diabète au cours d’une grossesse (passée ou présente) • Primigravida at 35 years of age and older, or 15 years of age and younger / Primigeste de 35 ans et plus ou de 15 ans et moins • History of thromboembolic disease / Antécédents de maladie thrombo- embolique • Pulmonary hypertension / Hypertension artérielle pulmonaire • Severe asthma or other chronic lung disease / Asthme grave ou autre (...) Statement on pregnancy and travel 1 CCDR Canada Communicable Disease Report RMTC Relevé des maladies transmissibles au Canada March 2010 • Volume 36 • ACS-2 March 2010 • Volume 36 • DCC-2 ISSN 1481-8531 Committee to Advise on Tropical Medicine and Travel* † STATEMENT ON PREGNANCY AND TRAVEL This correction note was published in the CCDR Volume 40-8 on April 17, 2014 The “Statement on Pregnancy and Travel” by the Committee to Advise on Tropical Medicine and Travel (CATMAT) † published in March

2010 CPG Infobase

168. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. (PubMed)

and 44 non-academic hospitals in the Netherlands. Women with non-severe hypertensive disorders of pregnancy between 34 and 37 weeks of gestation were randomly allocated to either induction of labour or caesarean section within 24 h (immediate delivery) or a strategy aimed at prolonging pregnancy until 37 weeks of gestation (expectant monitoring). The primary outcomes were a composite of adverse maternal outcomes (thromboembolic disease, pulmonary oedema, eclampsia, HELLP syndrome, placental abruption (...) Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. There is little evidence to guide the management of women with hypertensive disorders in late preterm pregnancy. We investigated the effect of immediate delivery versus expectant monitoring on maternal and neonatal outcomes in such women.We did an open-label, randomised controlled trial, in seven academic hospitals

2015 Lancet

169. Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome

of CYP3A4 and P-gp, such as: 14.a rifampin 14.b carbamazepine 14.c phenytoin 14.d St. John's wort 15. Intend pregnancy or breastfeeding within the next year 16. Have a known allergy to apixaban, rivaroxaban, or edoxaban 17. Have experienced thrombosis while receiving warfarin at a target INR of 2-3 and have been assigned a higher target INR at the discretion of their clinician. 18. Patients with active pathological bleeding. 19. A history of arterial thromboembolism (e.g., stroke, myocardial infarction (...) Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Thrombosis Thromboembolism Antiphospholipid Syndrome Disease Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Autoimmune Diseases Immune System Diseases Warfarin Apixaban Anticoagulants Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular

2014 Clinical Trials

170. Prophylaxis of Venous Thromboembolism After Bariatric Surgery

: Rijnstate Hospital Information provided by (Responsible Party): Frits Berends, Rijnstate Hospital Study Details Study Description Go to Brief Summary: This study is a prospective evaluation of the relationship between lean body weight and anti-Xa activity and 5700 International Units (IU) nadroparin 4 hours after subcutaneous administration in morbidly obese patients after bariatric surgery. Condition or disease Intervention/treatment Phase Morbid Obesity Thromboembolism Bypass Complications Drug (...) ) First Posted: November 20, 2014 Last Update Posted: November 20, 2014 Last Verified: November 2014 Keywords provided by Frits Berends, Rijnstate Hospital: Nadroparin Anti-Xa activity Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Obesity, Morbid Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Heparin, Low-Molecular-Weight Dalteparin Nadroparin

2014 Clinical Trials

171. Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging

, 2017 Sponsor: Massachusetts General Hospital Information provided by (Responsible Party): Robert Scott Harris, M.D., Massachusetts General Hospital Study Details Study Description Go to Brief Summary: This study with evaluate blood flow in the lungs of patients prior to and after surgery for treatment. Condition or disease Chronic Thromboembolic Pulmonary Hypertension Detailed Description: Specifically, we will evaluate the length-scale or size of blood flow alterations using filtering techniques (...) Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2014 Clinical Trials

172. Follow-up in Rivaroxaban Patients in Setting of Thromboembolism

anticoagulants (heparins and warfarin); 2. there will be less bleeding than when patients are on conventional anticoagulants; 3. there will be a lower long-term incidence of morbidity from chronic thromboembolic pulmonary hypertension and post-thrombotic limb syndrome. Condition or disease Intervention/treatment Venous Thromboembolism Other: Non-interventional study Detailed Description: United Kingdom-only prospective, non-interventional, investigator-led, multi-centre, single cohort, registry (...) relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Rivaroxaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants

2014 Clinical Trials

173. Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

physician, ongoing drug or alcohol addiction (> 8 drinks/week) Pregnancy /breast feeding Severely impaired renal function, GFR < 30 ml/min Impaired liver function (ALT/AST transaminase count 3fold higher than normal values) or liver disease with reduced life expectancy <1 year Valvular AF (moderate- severe mitral insufficiency; relevant mitral steno-sis with a mean pressure gradient >5mmHg) Long standing persistent (>12 months) and permanent AF NSTEMI/STEMI/implantated drug eluting stent with indication (...) Hospital, Bonn ClinicalTrials.gov Identifier: Other Study ID Numbers: MED2-201301 2013-003492-35 ( EudraCT Number ) First Posted: February 20, 2014 Last Update Posted: September 3, 2018 Last Verified: August 2018 Additional relevant MeSH terms: Layout table for MeSH terms Atrial Fibrillation Thromboembolism Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Embolism and Thrombosis Vascular Diseases Dabigatran Antithrombins Serine Proteinase Inhibitors Protease Inhibitors

2014 Clinical Trials

174. Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

will receive the study drug and 287 will receive an inactive substance. Analysis will be performed to assess the safety and the superiority of the study drug. Condition or disease Intervention/treatment Phase Venous Thromboembolism Cancer Drug: Apixaban Drug: Placebo drug Phase 2 Detailed Description: Patients holding a malignancy have a 7 to 28-fold higher risk for venous thromboembolism (VTE) than non-cancer patients(1). Since most cancer patients are currently treated in the outpatient setting, an acute (...) Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Apixaban Factor Xa Inhibitors Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticoagulants

2014 Clinical Trials

175. MERIT-2: Macitentan in thE tReatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension (OL)

: NCT02060721 Recruitment Status : Active, not recruiting First Posted : February 12, 2014 Last Update Posted : December 20, 2018 Sponsor: Actelion Information provided by (Responsible Party): Actelion Study Details Study Description Go to Brief Summary: Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Condition or disease Intervention/treatment Phase Chronic Thromboembolic Pulmonary (...) of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception. Exclusion Criteria: Permanent discontinuation of DB study treatment due to an hepatic adverse event or liver aminotransferase abnormalities. Any known factor (e.g., drug or substance abuse) or disease (e.g., unstable psychiatric illness) that, in the opinion of the investigator, may interfere with treatment compliance

2014 Clinical Trials

176. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. (PubMed)

Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Recommendations for venous thromboembolism (VTE) prophylaxis in patients with inflammatory bowel disease (IBD) can be refined by incorporating patient-specific risk factors.To determine the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in children and adults with Crohn's disease and ulcerative colitis and evaluate whether this risk varies by age (...) and/or presence of other risk factors.We performed a cohort study using Danish administrative data. Incidence rates of DVT and PE were calculated among patients with IBD and an age- and gender-matched comparison population and compared using Cox proportional hazards regression. We performed additional analyses stratifying by age, gender and disease type and restricting outcomes to unprovoked events (occurring without known malignancy, surgery, fracture/trauma or pregnancy). We next performed a nested case

2011 Gut

177. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. (PubMed)

years. Measures of calibration and discrimination undertaken in validation cohort.564 general practices in England and Wales contributing to the QResearch database.Patients aged 25-84 years, with no record of pregnancy in the preceding 12 months or any previous venous thromboembolism, and not prescribed oral anticoagulation at baseline: 2,314,701 in derivation cohort and 1,240,602 in validation cohort. Outcomes Incident cases of venous thromboembolism, either deep vein thrombosis or pulmonary (...) Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. To derive and validate a new clinical risk prediction algorithm (QThrombosis, www.qthrombosis.org) to estimate individual patients' risk of venous thromboembolism.Prospective open cohort study using routinely collected data from general practices. Cox proportional hazards models used in derivation cohort to derive risk equations evaluated at 1 and 5

Full Text available with Trip Pro

2011 BMJ

178. Aortic Diseases

aortic event improve steadily, a speci?c section is dedicated for chronicAD andfollow-upof patients aftertheacutephaseof AAS. Special emphasis is put on genetic and congenital aortic diseases, becausepreventivemeasuresplayanimportantroleinavoidingsub- sequent complications. Aortic diseases of elderly patients often present as thromboembolic diseases or atherosclerotic stenosis. Thecalci?edaortacanbeamajorproblemforsurgicalorinterven- tionalmeasures.Thecalci?ed‘coralreef’aortahastobeconsidered (...) Aortic Diseases ESC GUIDELINES 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC) Authors/Task Force members: Raimund Erbel * (Chairperson) (Germany), Victor Aboyans * (Chairperson) (France), Catherine Boileau (France), Eduardo Bossone (Italy), Roberto Di Bartolomeo

2014 European Society of Cardiology

179. Prevention of Thromboembolism in Spinal Cord Injury (Treatment)

cord injury, and following the cessation of prophylactic anticoagulation therapy, to be lower than during the first 3 months after the injury, measuring 1.25% (eight out of 640 patients). [ ] For patient education information, see , as well as and . See also , , , , , , , and . Next: Etiopathophysiology Patients with spinal cord injury (SCI) have a higher risk of thromboembolic disease related to the Virchow triad (ie, venous stasis, hypercoagulability, intimal injury). Stasis from paralyzed (...) other tests for detecting DVT of the calf muscle, has less sensitivity and specificity than Doppler ultrasonography, and is less sensitive to incomplete obstruction of a vein by DVT. In addition, extrinsic compression may give a positive result. Radiologic Studies The following imaging studies may be used in the diagnosis of thromboembolic disease: radiocontrast venography, Doppler ultrasonography, I-125 fibrinogen scintigraphy, and ventilation/perfusion scanning. Radiocontrast venography

2014 eMedicine.com

180. Prevention of Thromboembolism in Spinal Cord Injury (Overview)

cord injury, and following the cessation of prophylactic anticoagulation therapy, to be lower than during the first 3 months after the injury, measuring 1.25% (eight out of 640 patients). [ ] For patient education information, see , as well as and . See also , , , , , , , and . Next: Etiopathophysiology Patients with spinal cord injury (SCI) have a higher risk of thromboembolic disease related to the Virchow triad (ie, venous stasis, hypercoagulability, intimal injury). Stasis from paralyzed (...) other tests for detecting DVT of the calf muscle, has less sensitivity and specificity than Doppler ultrasonography, and is less sensitive to incomplete obstruction of a vein by DVT. In addition, extrinsic compression may give a positive result. Radiologic Studies The following imaging studies may be used in the diagnosis of thromboembolic disease: radiocontrast venography, Doppler ultrasonography, I-125 fibrinogen scintigraphy, and ventilation/perfusion scanning. Radiocontrast venography

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>